These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38553687)

  • 41. Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.
    Caroff SN; Mu F; Ayyagari R; Schilling T; Abler V; Carroll B
    BMC Psychiatry; 2018 Sep; 18(1):306. PubMed ID: 30249218
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Strategies for dosing and switching antipsychotics for optimal clinical management.
    Buckley PF; Correll CU
    J Clin Psychiatry; 2008; 69 Suppl 1():4-17. PubMed ID: 18484804
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pimozide for schizophrenia or related psychoses.
    Mothi M; Sampson S
    Cochrane Database Syst Rev; 2013 Nov; (11):CD001949. PubMed ID: 24194433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Estimating the Value of New Technologies That Provide More Accurate Drug Adherence Information to Providers for Their Patients with Schizophrenia.
    Shafrin J; Schwartz TT; Lakdawalla DN; Forma FM
    J Manag Care Spec Pharm; 2016 Nov; 22(11):1285-1291. PubMed ID: 27783545
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Systematic Review of Real-World Treatment Patterns of Oral Antipsychotics and Associated Economic Burden in Patients with Schizophrenia in the United States.
    Martin A; Bessonova L; Hughes R; Doane MJ; O'Sullivan AK; Snook K; Cichewicz A; Weiden PJ; Harvey PD
    Adv Ther; 2022 Sep; 39(9):3933-3956. PubMed ID: 35844007
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The impact of antipsychotic side effects on attitudes towards medication in people with schizophrenia and related disorders.
    Chiang YL; Klainin-Yobas P; Ignacio J; Chng CM
    J Clin Nurs; 2011 Aug; 20(15-16):2172-82. PubMed ID: 21539628
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary.
    Kane JM; Leucht S; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2003; 64 Suppl 12():5-19. PubMed ID: 14640142
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Reducing antipsychotic drugs in stable patients with chronic schizophrenia or schizoaffective disorder: a randomized controlled pilot trial.
    Huhn M; Leucht C; Rothe P; Dold M; Heres S; Bornschein S; Schneider-Axmann T; Hasan A; Leucht S
    Eur Arch Psychiatry Clin Neurosci; 2021 Mar; 271(2):293-302. PubMed ID: 32062728
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A cross-sectional observational study of healthcare professional views of factors affecting teenage adherence with antipsychotic medication.
    Ramdour S; Duxbury JA; Becket G; Wilson S
    J Psychiatr Ment Health Nurs; 2015 Sep; 22(7):491-501. PubMed ID: 25990303
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
    Takeuchi H; Suzuki T; Uchida H; Nakajima S; Nomura K; Kikuchi T; Manki H; Watanabe K; Kashima H
    J Clin Psychopharmacol; 2008 Oct; 28(5):540-3. PubMed ID: 18794650
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors associated with successful antipsychotic dose reduction in schizophrenia: a systematic review of prospective clinical trials and meta-analysis of randomized controlled trials.
    Tani H; Takasu S; Uchida H; Suzuki T; Mimura M; Takeuchi H
    Neuropsychopharmacology; 2020 Apr; 45(5):887-901. PubMed ID: 31770770
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cognitive behavioural therapy without medication for schizophrenia.
    Bighelli I; Çıray O; Salahuddin NH; Leucht S
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD015332. PubMed ID: 38323679
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risperidone (depot) for schizophrenia.
    Sampson S; Hosalli P; Furtado VA; Davis JM
    Cochrane Database Syst Rev; 2016 Apr; 4(4):CD004161. PubMed ID: 27078222
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.
    Lewis SW; Davies L; Jones PB; Barnes TR; Murray RM; Kerwin R; Taylor D; Hayhurst KP; Markwick A; Lloyd H; Dunn G
    Health Technol Assess; 2006 May; 10(17):iii-iv, ix-xi, 1-165. PubMed ID: 16707074
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Letter to the Editor: Rethinking The Cost Of Antipsychotic Treatment: The Average Cost Of The Drugs Used In Turkey In 2020.
    Yıldız M; Osman E
    Turk Psikiyatri Derg; 2022; 33(2):146-148. PubMed ID: 35730516
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Is our clinical practice of antipsychotic relapse prevention in schizophrenia really evidence-based].
    Schanda H; Stompe T
    Neuropsychiatr; 2010; 24(1):14-26. PubMed ID: 20146916
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Association of antipsychotic treatment switching in patients with schizophrenia, bipolar, and major depressive disorders.
    Ayyagari R; Thomason D; Mu F; Philbin M; Carroll B
    J Med Econ; 2020 Feb; 23(2):204-212. PubMed ID: 31663802
    [No Abstract]   [Full Text] [Related]  

  • 59. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of schizophrenia and related disorders.
    Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for the Treatment of Schizophrenia and Related Disorders
    Aust N Z J Psychiatry; 2005; 39(1-2):1-30. PubMed ID: 15660702
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictors of discontinuation of antipsychotic medication and subsequent outcomes in the European First Episode Schizophrenia Trial (EUFEST).
    Landolt K; Rössler W; Ajdacic-Gross V; Derks EM; Libiger J; Kahn RS; Fleischhacker WW;
    Schizophr Res; 2016 Apr; 172(1-3):145-51. PubMed ID: 26922655
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.